RESUMEN
Chemotherapy-induced neutropenia (FN) is the most common infectious complication in pediatric oncology. To our knowledge, no pediatric research has been published in Tunisia. The purpose of our study was to describe the features of FN among Tunisian children and to investigate factors correlated with FN. We conducted a prospective study of children with chemotherapy-induced FN at the Department of Pediatric Medicine A of the Tunis Children´s Hospital from July 2019 to December 2019. We recorded 50 episodes of FN in 32 patients whose mean age was 5.3 years (3 months-16 years). We included 26 patients with solid tumors (81%) and six patients with hemopathies (18.7%). The mean time between last treatment and fever onset was 10.67 days. Bacteriological investigation was contributory in 18% of cases and mainly showed gram positive cocci. Therapeutic protocol including 1st line empirical antibiotic therapy (3rd generation cephalosporin with aminoglycoside) was effective in 62% of cases. Mortality rate of patients with FN was 2%. The statistical study did not reveal any factor of correlation with late-onset neutropenia. In conclusion, our results are consistent with literature data on bacteriological documentation and mortality. Our 1st line treatment option based on 3rd generation cephalosporin associated with aminoglycoside was effective in 2/3 of the cases. In the future, oral antibiotics may be considered in patients at low risk for infection.
Asunto(s)
Antineoplásicos , Neutropenia Febril Inducida por Quimioterapia , Neoplasias , Aminoglicósidos/uso terapéutico , Antibacterianos , Antineoplásicos/efectos adversos , Cefalosporinas/uso terapéutico , Neutropenia Febril Inducida por Quimioterapia/complicaciones , Neutropenia Febril Inducida por Quimioterapia/tratamiento farmacológico , Niño , Preescolar , Humanos , Neoplasias/tratamiento farmacológico , Neoplasias/patología , Estudios ProspectivosRESUMEN
La bacteriemia representa una importante causa de morbimortalidad en pacientes oncológicos. Durante el episodio de neutropenia inducida por quimioterapia, un 15%25% de los pacientes tendrá bacteriemia. Objetivo: identificar factores de riesgo asociados con bacteriemia en pacientes oncológicos pediátricos con neutropenia y fiebre. Material y métodos: estudio de cohorte prospectivo. Se incluyeron pacientes con enfermedades hematooncológicas y neutropenia febril, internados en un hospital pediátrico de alta complejidad entre julio de 2018 y mayo de 2019. Se excluyeron receptores de trasplante de médula ósea. Se compararon las características clínicas según se documentara bacteriemia (B) o no. Resultados: Se incluyeron 160 pacientes (p). Eran varones 93 (58%). La mediana de edad fue 81,5 meses (RIC 36-127,5). La enfermedad de base (EB) más frecuente fue: leucemia linfoblástica aguda (LLA) 88 (55%). Se identificaron 20 (12,5%) pacientes con bacteriemia (B). En el análisis univariado hubo asociación entre B y LMA (p=0,003) y la internación en UCI (p=0,0001). En el modelo multivariado, ajustado por el resto de las variables, se identificaron la LMA (OR 8,24, IC95% 2,5-26,4; p<0,001) y la tiflitis (OR 5,86, IC95% 1,2-27,3; p=0,02) como factores relacionados con bacteriemia. Los principales microorganismos identificados fueron: estreptococos del grupo viridans 6 (30%), Escherichia coli 4 (20%) y estafilococos coagulasa negativos 3 (15%). Quince (75%) fueron bacteriemias secundarias a un foco clínico. El foco más frecuente fue el mucocutáneo (n=7, 35%). En esta cohorte de niños con cáncer y neutropenia febril, los factores asociados con bacteriemia fueron: la LMA, la tiflitis y la internación en UCI (AU)
Bacteremia is an important cause of morbidity and mortality in oncology patients. During an episode of chemotherapy-induced neutropenia, 15%-25% of patients will develop bacteremia. Objective: to identify risk factors associated with bacteremia in pediatric oncology patients with neutropenia and fever. Material and methods: prospective cohort study. Patients with hematology-oncology diseases and febrile neutropenia, admitted to a tertiary-care pediatric hospital between July 2018 and May 2019 were included. Bone marrow transplant recipients were excluded. Clinical characteristics were compared according to whether or not bacteremia was recorded. Results: 160 patients were included of whom 93 (58%) were male. Median age was 81.5 months (IQR 36-127.5). The most common underlying disease was acute lymphoblastic leukemia (ALL) in 88 patients (55%). Twenty (12.5%) patients with bacteremia were identified. In univariate analysis, an association was found between bacteremia and acute myeloid leukemia (AML) (p=0.003) and ICU admission (p=0.0001). In the multivariate model, adjusted for the remaining variables, AML (OR 8.24; 95%CI 2.5-26.4; p<0.001) and typhlitis (OR 5.86; 95%CI 1.2-27.3; p=0.02) were identified as factors related to bacteremia. The main microorganisms identified were viridans group streptococci in 6 (30%), Escherichia coli in 4 (20%), and coagulase negative staphylococci in 3 (15%). In 15 cases (75%), bacteremia was secondary to a clinical focus. The most frequent focus was mucocutaneous (n=7, 35%). In this cohort of children with cancer and febrile neutropenia, the factors associated with bacteremia were AML, typhlitis, and ICU admission (AU)
Asunto(s)
Humanos , Lactante , Preescolar , Niño , Adolescente , Factores de Riesgo , Bacteriemia/etiología , Bacteriemia/epidemiología , Leucemia-Linfoma Linfoblástico de Células Precursoras/complicaciones , Neutropenia Febril Inducida por Quimioterapia/complicaciones , Neoplasias/complicaciones , Estudios Prospectivos , Estudios de Cohortes , Huésped InmunocomprometidoRESUMEN
INTRODUCTION: This study was conducted to develop and validate a nomogram for predicting the risk of neutropenia or febrile neutropenia (FN) in tumor patients in the first cycle of etoposide-based chemotherapy. METHODS: This retrospective cohort study used an information system to monitor patients with non-Hodgkin's lymphoma or solid tumors receiving an etoposide regimen in the first chemotherapy cycle in our hospital from 2009 to 2020. Binary logistic regression analysis was used to identify the influencing factors of patients with neutropenia or FN. Those factors were then used to develop a nomogram. RESULTS: A total of 1,554 patients were divided into the development group (n = 1,072) and validation group (n = 482). Variables used to predict neutropenia or FN were Karnofsky performance status (odds ratio [OR] = 0.85, 95% confidence interval [CI] = 0.81-0.89, p < 0.01), metastatic sites ≥3 (OR = 6.33, 95% CI = 2.66-15.11, p < 0.01), comorbidity of heart disease (OR = 4.88, 95% CI = 1.74-13.67, p < 0.01), recent surgery (OR = 7.96, 95% CI = 1.96-32.36, p < 0.01), administration of alkylating agents (OR = 4.50, 95% CI = 1.10-18.48, p < 0.01), total bilirubin ≥25 µmol/L (OR = 11.42, 95% CI = 4.00-32.61, p < 0.01), and lymphocyte count <0.7 × 109/L (OR = 4.22, 95% CI = 2.00-9.75, p < 0.01). CONCLUSION: This model can aid the early identification and screening of the potential risk of neutropenia or FN in the first cycle of treatment for patients using etoposide-based chemotherapy.
Asunto(s)
Antineoplásicos Fitogénicos/efectos adversos , Neutropenia Febril Inducida por Quimioterapia/diagnóstico , Neutropenia Febril Inducida por Quimioterapia/epidemiología , Etopósido/efectos adversos , Neoplasias/tratamiento farmacológico , Anciano , Antineoplásicos Fitogénicos/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neutropenia Febril Inducida por Quimioterapia/complicaciones , Etopósido/uso terapéutico , Femenino , Humanos , Modelos Logísticos , Masculino , Persona de Mediana Edad , Neoplasias/complicaciones , Nomogramas , Valor Predictivo de las Pruebas , Curva ROC , Estudios Retrospectivos , Medición de RiesgoRESUMEN
Not available.
Asunto(s)
Betacoronavirus , Neutropenia Febril Inducida por Quimioterapia/prevención & control , Infecciones por Coronavirus/prevención & control , Factor Estimulante de Colonias de Granulocitos/uso terapéutico , Neoplasias/tratamiento farmacológico , Pandemias/prevención & control , Neumonía Viral/prevención & control , COVID-19 , Neutropenia Febril Inducida por Quimioterapia/complicaciones , Infecciones por Coronavirus/complicaciones , Infecciones por Coronavirus/inmunología , Factor Estimulante de Colonias de Granulocitos/efectos adversos , Humanos , Neumonía Viral/complicaciones , Neumonía Viral/inmunología , SARS-CoV-2RESUMEN
Patients undergoing myeloablative chemotherapy and hematopoietic stem cell transplantation (HSCT) experience profound neutropenia and vulnerability to infection. Previous research has indicated that patients with infections have depleted vitamin C status. In this study, we recruited 38 patients with hematopoietic cancer who were undergoing conditioning chemotherapy and HSCT. Blood samples were collected prior to transplantation, at one week, two weeks and four weeks following transplantation. Vitamin C status and biomarkers of inflammation (C-reactive protein) and oxidative stress (protein carbonyls and thiobarbituric acid reactive substances) were assessed in association with febrile neutropenia. The vitamin C status of the study participants decreased from 44 ± 7 µmol/L to 29 ± 5 µmol/L by week one (p = 0.001) and 19 ± 6 µmol/L by week two (p < 0.001), by which time all of the participants had undergone a febrile episode. By week four, vitamin C status had increased to 37 ± 10 µmol/L (p = 0.1). Pre-transplantation, the cohort comprised 19% with hypovitaminosis C (i.e., <23 µmol/L) and 8% with deficiency (i.e., <11 µmol/L). At week one, those with hypovitaminosis C had increased to 38%, and at week two, 72% had hypovitaminosis C, and 34% had outright deficiency. C-reactive protein concentrations increased from 3.5 ± 1.8 mg/L to 20 ± 11 mg/L at week one (p = 0.002), and 119 ± 25 mg/L at week two (p < 0.001), corresponding to the development of febrile neutropenia in the patients. By week four, these values had dropped to 17 ± 8 mg/L (p < 0.001). There was a significant inverse correlation between C-reactive protein concentrations and vitamin C status (r = -0.424, p < 0.001). Lipid oxidation (thiobarbituric acid reactive substances (TBARS)) increased significantly from 2.0 ± 0.3 µmol/L at baseline to 3.3 ± 0.6 µmol/L by week one (p < 0.001), and remained elevated at week two (p = 0.003), returning to baseline concentrations by week four (p = 0.3). Overall, the lowest mean vitamin C values (recorded at week two) corresponded with the highest mean C-reactive protein values and lowest mean neutrophil counts. Thus, depleted vitamin C status in the HSCT patients coincides with febrile neutropenia and elevated inflammation and oxidative stress.
Asunto(s)
Deficiencia de Ácido Ascórbico , Ácido Ascórbico/sangre , Neutropenia Febril Inducida por Quimioterapia , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Agonistas Mieloablativos , Anciano , Deficiencia de Ácido Ascórbico/complicaciones , Deficiencia de Ácido Ascórbico/etiología , Neutropenia Febril Inducida por Quimioterapia/complicaciones , Neutropenia Febril Inducida por Quimioterapia/etiología , Femenino , Neoplasias Hematológicas/terapia , Humanos , Huésped Inmunocomprometido , Inflamación , Masculino , Persona de Mediana Edad , Agonistas Mieloablativos/efectos adversos , Agonistas Mieloablativos/uso terapéutico , Estrés Oxidativo/fisiologíaRESUMEN
BACKGROUND: Fungal infections are a major complication of neutropaenia following chemotherapy. Their early diagnosis is difficult, and empirical antifungal treatment is widely used, and uses of less toxic drugs that reduce breakthrough infection are required. OBJECTIVE: We conducted a multicentre, open-label, randomised, non-inferiority trial to compare the safety and efficacy of intravenous itraconazole (ivITCZ) and liposomal amphotericin B (LAmB) as empirical antifungal therapy in patients with haematological malignancies with neutropaenia and persistent fever. METHODS: Patients with haematological malignancies who developed fever refractory to broad-spectrum antibacterial agents under neutropaenia conditions were enrolled. Patients were randomised for treatment with LAmB (3.0 mg/kg/d) or ivITCZ (induction: 400 mg/d, maintenance: 200 mg/d). RESULTS: Observed overall favourable response rates of 17/52 (32.7%) and 18/50 (36.0%) in the LAmB and ivITCZ groups, with a model-based estimate of a 4% difference (90% CI, -12% to 20%), did not fulfil the statistical non-inferiority criterion. In the LAmB group, there were two cases of breakthrough infection and five cases of probable invasive fungal disease, whereas in the itraconazole group, neither breakthrough infection nor probable invasive fungal disease occurred. Patients in the ivITCZ group had significantly fewer grade 3-4 hypokalaemia-related events than LAmB group patients (P < .01). The overall incidence of adverse events tended to be lower in the ivITCZ group (P = .07). CONCLUSION: ivITCZ showed similar efficacy and safety as LAmB as empirical antifungal therapy in haematological malignancy patients with febrile neutropaenia, although the small sample size and various limitations prevented demonstration of its non-inferiority.
Asunto(s)
Anfotericina B , Neutropenia Febril Inducida por Quimioterapia/complicaciones , Itraconazol , Micosis , Administración Intravenosa , Adulto , Anciano , Anfotericina B/administración & dosificación , Anfotericina B/uso terapéutico , Antifúngicos/administración & dosificación , Antifúngicos/uso terapéutico , Neutropenia Febril Inducida por Quimioterapia/patología , Femenino , Neoplasias Hematológicas/complicaciones , Neoplasias Hematológicas/patología , Humanos , Itraconazol/administración & dosificación , Itraconazol/uso terapéutico , Masculino , Persona de Mediana Edad , Micosis/tratamiento farmacológico , Micosis/etiología , Adulto JovenRESUMEN
BACKGROUND: Invasive fungal disease is a major cause of morbidity and mortality in children with cancer and high-risk febrile neutropenia (HRFN). Repeated serum galactomannan (sGM) measurements have been described as an effective tool to guide therapy in adults under suspicion of invasive aspergillosis. However, the utility of this approach has not been reported in paediatric population. OBJECTIVES: To evaluate the usefulness of sGM measurements in initiating and modifying antifungal therapy (AFT) in children with cancer and persistent HRFN. PATIENTS/METHODS: Nested case-control study in children with cancer and persistent HRFN episodes, between July 2013 and January 2019. Patients were classified as cases and controls depending on if they received AFT or not, respectively. Through odds ratio analysis, we assessed the role of sGM positivity in the AFT initiation decision. Then, we analysed the group of patients that initiated AFT, and compared those who had AFT modifications and those who did not, analysing different sGM kinetics thresholds. RESULTS: A total of 191 episodes from children with persistent HRFN were enrolled, of which 107 received AFT and 84 did not. The median age was 7 years (IQR 4-12), 52% were male and 89% had a haematologic malignancy as underlying disease. Positive sGM was not associated with AFT initiation (OR 0.99, 95% CI 0.43-2.33, P = .99). A difference threshold in sGM Δ ≥ 0.3 sGM was significantly associated with AFT modification (OR 5.07, 95% CI 1.02- 25.70, P = .04). CONCLUSIONS: Our results suggest the utility of serial sGM sampling during AFT in children with persistent HRFN.
Asunto(s)
Antifúngicos/uso terapéutico , Neutropenia Febril Inducida por Quimioterapia/complicaciones , Infecciones Fúngicas Invasoras/tratamiento farmacológico , Mananos/sangre , Neoplasias/complicaciones , Aspergilosis/tratamiento farmacológico , Estudios de Casos y Controles , Niño , Femenino , Galactosa/análogos & derivados , Neoplasias Hematológicas/complicaciones , Humanos , Aspergilosis Pulmonar Invasiva/tratamiento farmacológico , MasculinoRESUMEN
BACKGROUND: Bacillus cereus sometimes causes central nervous system infection, especially in compromised hosts. In cases of meningitis arising during neutropenia, CSF abnormalities tend to be subtle and can be easily overlooked, and mortality rate is high. We report a survived case of B. cereus meningitis/brain abscess in severe neutropenia, presenting as immune reconstitution syndrome. CASE PRESENTATION: A 54-year-old Japanese female with acute myelogenous leukemia developed B. cereus bacteremia and meningitis during consolidation chemotherapy. At the onset, she presented with mild meningism. She had marked leukocytopenia (WBC <100/µL, neutrophils 0/µL) and lumbar puncture yielded only mild pleocytosis. She was transferred to intensive care unit, and meropenem, linezolid and vancomycin was started. With intensive therapy, she recovered and once became afebrile. On day 19, however, her fever, meningism and consciousness level dramatically worsened despite recovery of bone marrow function. The antimicrobial chemotherapy was continued and finally she was cured with no complications. CONCLUSIONS: With early diagnosis and prompt initiation and of antibiotics, the case was successfully treated without any sequelae. It is important to remember that, even under optimal antimicrobial therapy, bone marrow recovery can cause transient reaggravation of the disease. In such cases, timely and appropriate evaluation should be done to make the clinical decision to change, continue, or intensify treatment.
Asunto(s)
Bacteriemia/complicaciones , Absceso Encefálico/complicaciones , Neutropenia Febril Inducida por Quimioterapia/complicaciones , Síndrome Inflamatorio de Reconstitución Inmune/complicaciones , Meningitis Bacterianas/complicaciones , Antibacterianos/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Bacillus cereus/aislamiento & purificación , Bacteriemia/tratamiento farmacológico , Bacteriemia/microbiología , Absceso Encefálico/tratamiento farmacológico , Absceso Encefálico/microbiología , Femenino , Humanos , Síndrome Inflamatorio de Reconstitución Inmune/tratamiento farmacológico , Síndrome Inflamatorio de Reconstitución Inmune/microbiología , Leucemia Mieloide Aguda/tratamiento farmacológico , Meningitis Bacterianas/tratamiento farmacológico , Meningitis Bacterianas/microbiología , Persona de Mediana Edad , Resultado del TratamientoRESUMEN
Background/aim: Bacteremia remains an important cause of morbidity and mortality during febrile neutropenia (FN) episodes. We aimed to define the risk factors for bacteremia in febrile neutropenic children with hemato-oncological malignancies. Materials and methods: The records of 150 patients aged ≤18 years who developed FN in hematology and oncology clinics were retrospectively evaluated. Patients with bacteremia were compared to patients with negative blood cultures. Results: The mean age of the patients was 7.5 ± 4.8 years. Leukemia was more prevalent than solid tumors (61.3% vs. 38.7%). Bacteremia was present in 23.3% of the patients. Coagulase-negative staphylococci were the most frequently isolated microorganism. Leukopenia, severe neutropenia, positive peripheral blood and central line cultures during the previous 3 months, presence of a central line, previous FN episode(s), hypotension, tachycardia, and tachypnea were found to be risk factors for bacteremia. Positive central line cultures during the previous 3 months and presence of previous FN episode(s) were shown to increase bacteremia risk by 2.4-fold and 2.5-fold, respectively. Conclusion: Presence of a bacterial growth in central line cultures during the previous 3 months and presence of any previous FN episode(s) were shown to increase bacteremia risk by 2.4-fold and 2.5-fold, respectively. These factors can predict bacteremia in children with FN.
Asunto(s)
Bacteriemia , Neutropenia Febril Inducida por Quimioterapia , Adolescente , Bacteriemia/complicaciones , Bacteriemia/epidemiología , Bacteriemia/fisiopatología , Neutropenia Febril Inducida por Quimioterapia/complicaciones , Neutropenia Febril Inducida por Quimioterapia/epidemiología , Neutropenia Febril Inducida por Quimioterapia/fisiopatología , Niño , Preescolar , Femenino , Humanos , Masculino , Neoplasias/complicaciones , Neoplasias/epidemiología , Estudios Retrospectivos , Factores de RiesgoRESUMEN
We report the first case of liver abscess due to Sterigmatomyces halophilus. Because this pathogen grows poorly in culture medium without added salts, it was identified by sequencing analysis targeting the rRNA gene internal transcribed spacer (ITS) region. This method could be useful for pathogens that cannot be cultured using standard methods.
Asunto(s)
Antifúngicos/uso terapéutico , Basidiomycota/aislamiento & purificación , Absceso Hepático/microbiología , Micosis/microbiología , Leucemia-Linfoma Linfoblástico de Células Precursoras/terapia , Anfotericina B/uso terapéutico , Antineoplásicos/efectos adversos , Basidiomycota/inmunología , Biopsia , Trasplante de Médula Ósea , Cefalosporinas/uso terapéutico , Neutropenia Febril Inducida por Quimioterapia/complicaciones , Neutropenia Febril Inducida por Quimioterapia/tratamiento farmacológico , Neutropenia Febril Inducida por Quimioterapia/inmunología , Niño , Trasplante de Células Madre Hematopoyéticas , Humanos , Hígado/microbiología , Hígado/patología , Absceso Hepático/diagnóstico , Absceso Hepático/tratamiento farmacológico , Absceso Hepático/inmunología , Masculino , Micafungina/uso terapéutico , Micosis/diagnóstico , Micosis/tratamiento farmacológico , Micosis/inmunología , Recurrencia Local de Neoplasia/inmunología , Recurrencia Local de Neoplasia/terapia , Leucemia-Linfoma Linfoblástico de Células Precursoras/inmunología , Resultado del Tratamiento , CefozopránRESUMEN
BACKGROUND: Piperacillin-tazobactam is commonly used in neutropenic sepsis at standard doses that do not account for inter-individual differences in age, bodyweight and renal function. This study was designed to assess the rate of attainment of pharmacokinetic/pharmacodynamic (PK/PD) targets in patients receiving piperacillin/tazobactam therapy and to evaluate the effect on clinical outcomes. METHODS: Patients undergoing intensive chemotherapy for aggressive hematological malignancies were enrolled and treated with piperacillin/tazobactam 4 g/0.5 g every 6 h as initial antimicrobial therapy for first fever. Plasma drug concentrations were assayed at 50% and 100% of the dosing interval and compared with target MIC breakpoint of 16 mg/L to calculate the primary endpoints of 50% and 100% time above MIC (fT > MIC), respectively. Secondary endpoints included time to clinical cure, length of hospital stay, duration of antibiotics, and clinical treatment success. RESULTS: Fifty-eight percent (14/24) of patients achieved 50% fT > MIC while only 4% (1/24) achieved 100% fT > MIC. Higher creatinine clearance was significantly associated with lower trough drug concentration and appeared to be the dominant reason for the poor PK/PD target attainment. Median time to clinical cure, duration of antibiotic therapy, and hospital length of stay was 3, 13 and 21 days, respectively. There were no statistically significant differences in these outcomes between patients who did and did not achieve 100% fT > MIC. CONCLUSIONS: A significant majority of febrile neutropenic patients fail to achieve PK/PD targets with 6-hourly piperacillin dosing, although the clinical implications of this finding are unclear. Larger studies are needed to assess any impact on morbidity and mortality. This trial is registered on the ANZCTR (ACTRN12618000110280).
Asunto(s)
Antibacterianos/farmacología , Antineoplásicos/efectos adversos , Neutropenia Febril Inducida por Quimioterapia/inmunología , Neoplasias Hematológicas/tratamiento farmacológico , Combinación Piperacilina y Tazobactam/farmacología , Sepsis/tratamiento farmacológico , Adulto , Anciano , Antibacterianos/uso terapéutico , Neutropenia Febril Inducida por Quimioterapia/complicaciones , Femenino , Humanos , Tiempo de Internación/estadística & datos numéricos , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Combinación Piperacilina y Tazobactam/uso terapéutico , Sepsis/inmunología , Sepsis/microbiología , Factores de Tiempo , Resultado del TratamientoRESUMEN
Raoultella planticola is a gram-negative, encapsulated, aerobic bacterium within the Enterobacteriaceae family. It has been primarily described as pathogen in cases with pneumonia and gastrointestinal infections. Here we describe a case of severe pelvic cellulitis in a patient with neutropenia following induction therapy for myeloid sarcoma. The patient experienced a septic shock and was treated successfully with antibiotic therapy. A literature review is provided to put this case in context with previous reports on R. planticola. This report highlights that awareness for uncommon pathogens is crucial in the clinical management of infections in neutropenic patients.
Asunto(s)
Antibacterianos/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Celulitis (Flemón)/microbiología , Neutropenia Febril Inducida por Quimioterapia/complicaciones , Infecciones por Enterobacteriaceae/microbiología , Enterobacteriaceae/aislamiento & purificación , Adulto , Celulitis (Flemón)/complicaciones , Celulitis (Flemón)/diagnóstico , Celulitis (Flemón)/tratamiento farmacológico , Neutropenia Febril Inducida por Quimioterapia/diagnóstico , Neutropenia Febril Inducida por Quimioterapia/etiología , Infecciones por Enterobacteriaceae/complicaciones , Infecciones por Enterobacteriaceae/diagnóstico , Infecciones por Enterobacteriaceae/tratamiento farmacológico , Humanos , Imagen por Resonancia Magnética , Masculino , Pelvis/diagnóstico por imagen , Sarcoma Mieloide/tratamiento farmacológico , Resultado del TratamientoRESUMEN
Background: Posaconazole is used for the prophylaxis of invasive fungal disease (IFD). Previous studies have shown it to be cost-effective compared to fluconazole/itraconazole. However, posaconazole has never been economically evaluated in developing countries. Aims: The aim of the present study was to perform a cost-effectiveness analysis of posaconazole compared to fluconazole in public (SUS) and private hospitals (PHS) in Brazil. Methods: A cost-effectiveness simulation was conducted on the basis of a pivotal study on the use of posaconazole in acute myeloid leukemia (AML) patients, adjusting the costs to Brazilian data. Results: A pharmacoeconomic analysis was performed on a hypothetical sample of 100 patients in each drug group. The total cost of posaconazole use alone was USD$ 220,656.31, whereas that for fluconazole was USD$ 83,875.00. Our results showed that patients with IFD remain hospitalized for an additional 12 days, at an average cost of USD$ 850.85 per patient per day. The total money spent by PHS for 100 patients for 100 days was USD$ 342,318.00 for the posaconazole group and USD$ 302,039.00 for the fluconazole group. An analysis of sensitivity (10%) revealed no intergroup difference. Conclusions: In Brazil posaconazole is cost-effective, and should be considered for the prophylaxis of patients with AMD/myelodysplasia (AML/MDS) undergoing chemotherapy
Antecedentes: El posaconazol se utiliza para la profilaxis de la enfermedad fúngica invasora (EFI). Algunos estudios han demostrado su rentabilidad en comparación con el fluconazol o el itraconazol. Sin embargo, el posaconazol nunca se había evaluado económicamente en el contexto de los países en vías de desarrollo. Objetivos: El objetivo de este estudio fue realizar un análisis de rentabilidad del posaconazol en comparación con el fluconazol en hospitales públicos (SUS) y hospitales privados (PHS) de Brasil. Métodos: Se realizó una simulación de rentabilidad basada en un estudio fundamental para el uso de posaconazol en pacientes con leucemia mieloide aguda (LMA) que adaptaba los costes a los datos brasileños. Resultados: Se realizó un análisis farmacoeconómico de 100 pacientes con cada grupo tratado. El gasto total de 100 días para los antifúngicos evaluados fue 220.656,31 $ para el posaconazol y de 83.875,00 $ para el fluconazol. Los pacientes con EFI permanecen en el hospital una media de 12 días más a un coste medio de 850,85 $ por día y paciente. El gasto total en PHS de 100 pacientes fue 342.318,00 $ para el grupo del posaconazol y 302.039,00 $ para el del fluconazol. No hubo diferencias entre los grupos al realizar un análisis de sensibilidad al 10%. Conclusiones: En Brasil, el posaconazol es rentable y debe tenerse en cuenta al elegir la profilaxis ideal para pacientes con LMA tratados con quimioterapia
Asunto(s)
Humanos , Micosis/tratamiento farmacológico , Antifúngicos/uso terapéutico , Fungemia/tratamiento farmacológico , Neutropenia Febril Inducida por Quimioterapia/complicaciones , Levaduras/patogenicidad , Brasil/epidemiología , Análisis Costo-Beneficio , Costos de los Medicamentos/estadística & datos numéricos , Fluconazol/economía , Itraconazol/economía , Huésped Inmunocomprometido , Leucemia Mieloide Aguda/complicaciones , Antineoplásicos/efectos adversos , Triazoles/economíaRESUMEN
BACKGROUND: Posaconazole is used for the prophylaxis of invasive fungal disease (IFD). Previous studies have shown it to be cost-effective compared to fluconazole/itraconazole. However, posaconazole has never been economically evaluated in developing countries. AIMS: The aim of the present study was to perform a cost-effectiveness analysis of posaconazole compared to fluconazole in public (SUS) and private hospitals (PHS) in Brazil. METHODS: A cost-effectiveness simulation was conducted on the basis of a pivotal study on the use of posaconazole in acute myeloid leukemia (AML) patients, adjusting the costs to Brazilian data. RESULTS: A pharmacoeconomic analysis was performed on a hypothetical sample of 100 patients in each drug group. The total cost of posaconazole use alone was USD$ 220,656.31, whereas that for fluconazole was USD$ 83,875.00. Our results showed that patients with IFD remain hospitalized for an additional 12 days, at an average cost of USD$ 850.85 per patient per day. The total money spent by PHS for 100 patients for 100 days was USD$ 342,318.00 for the posaconazole group and USD$ 302,039.00 for the fluconazole group. An analysis of sensitivity (10%) revealed no intergroup difference. CONCLUSIONS: In Brazil posaconazole is cost-effective, and should be considered for the prophylaxis of patients with AMD/myelodysplasia (AML/MDS) undergoing chemotherapy.
Asunto(s)
Antifúngicos/economía , Costos de los Medicamentos/estadística & datos numéricos , Hospitales Privados/economía , Hospitales Públicos/economía , Micosis/prevención & control , Triazoles/economía , Brasil , Neutropenia Febril Inducida por Quimioterapia/complicaciones , Costo de Enfermedad , Análisis Costo-Beneficio , Países en Desarrollo/economía , Fluconazol/economía , Humanos , Huésped Inmunocomprometido , Itraconazol/economía , Leucemia Mieloide Aguda/complicaciones , Micosis/economía , Micosis/etiologíaRESUMEN
OBJECTIVES: To study the management of chronic disseminated candidiasis (CDC) in patients presenting with acute leukemia. PATIENTS AND METHODS: Single-center retrospective study of acute leukemia patients (2006-2015) to investigate three aspects of CDC: its impact on the time interval between diagnosis and hematopoietic stem cell transplantation, when required (non-parametric Wilcoxon-Mann-Whitney test); its impact on overall survival (Cox proportional hazard regression model); antifungal therapeutic strategies implemented. RESULTS: A total of 639 patients presenting with acute leukemia were included; 144 were transplanted and 29 developed CDC. CDC did not significantly increase the time interval between diagnosis and transplantation, nor did it impact the overall survival of recipients. An improved overall survival was observed in non-transplanted acute leukemia patients presenting with CDC. CONCLUSION: CDC should not postpone transplantation if antifungal treatment is optimized.
Asunto(s)
Candidiasis/etiología , Trasplante de Células Madre Hematopoyéticas , Leucemia/complicaciones , Infecciones Oportunistas/etiología , Enfermedad Aguda , Corticoesteroides/uso terapéutico , Adulto , Aloinjertos , Antifúngicos/uso terapéutico , Candidiasis/tratamiento farmacológico , Candidiasis/mortalidad , Neutropenia Febril Inducida por Quimioterapia/complicaciones , Enfermedad Crónica , Terapia Combinada , Femenino , Humanos , Leucemia/tratamiento farmacológico , Leucemia/mortalidad , Leucemia/terapia , Masculino , Persona de Mediana Edad , Síndromes Mielodisplásicos/complicaciones , Síndromes Mielodisplásicos/terapia , Infecciones Oportunistas/tratamiento farmacológico , Infecciones Oportunistas/mortalidad , Modelos de Riesgos Proporcionales , Estudios Retrospectivos , Estadísticas no Paramétricas , Tiempo de Tratamiento , Acondicionamiento Pretrasplante/efectos adversos , Adulto JovenAsunto(s)
Anticuerpos Biespecíficos/efectos adversos , Antineoplásicos Inmunológicos/efectos adversos , Diagnóstico Diferencial , Tricosporonosis/diagnóstico , Infección por el Virus de la Varicela-Zóster/diagnóstico , Adulto , Anticuerpos Biespecíficos/uso terapéutico , Antifúngicos/uso terapéutico , Antineoplásicos Inmunológicos/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Antivirales/uso terapéutico , Neutropenia Febril Inducida por Quimioterapia/complicaciones , Femenino , Humanos , Leucemia-Linfoma Linfoblástico de Células Precursoras/complicaciones , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamiento farmacológico , Recurrencia , Terapia Recuperativa , Tricosporonosis/tratamiento farmacológico , Tricosporonosis/etiologíaRESUMEN
PURPOSE: To validate a clinical risk prediction score (Ammann score) to predict adverse events (AEs) in paediatric febrile neutropenia (FN). PATIENTS AND METHODS: Patients <16 years of age were enrolled. A risk prediction score (based on haemoglobin ≥ 9 g/dl, white cell count (WCC) < 0.3 G/l, platelet count <50 G/l and chemotherapy more intensive than acute lymphoblastic leukaemia maintenance therapy) was calculated and AEs were documented. RESULTS: In total, 100 FN episodes occurred in 52 patients, male:female ratio was 1.8:1 and median age was 56 months. At reassessment, AEs occurred in 18 of 55 (45%) low-risk FN episodes (score < 9) and 21 of 42 (55%) high-risk episodes (score ≥9) (sensitivity 60%, specificity 65%, positive predictive value 53%, negative predictive value 71%). Total WCC and absolute monocyte count (AMC) were significantly associated with AEs. CONCLUSION: This study identified total WCC and AMC as significantly associated with AEs but failed to validate the risk prediction score.
Asunto(s)
Antineoplásicos/efectos adversos , Neutropenia Febril/inducido químicamente , Fiebre/inducido químicamente , Neoplasias/tratamiento farmacológico , Medición de Riesgo/métodos , Neutropenia Febril Inducida por Quimioterapia/complicaciones , Niño , Preescolar , Neutropenia Febril/sangre , Neutropenia Febril/complicaciones , Femenino , Fiebre/sangre , Fiebre/complicaciones , Hemoglobinas/metabolismo , Humanos , Masculino , Neoplasias/complicaciones , Recuento de Plaquetas , Valor Predictivo de las Pruebas , Reproducibilidad de los Resultados , Factores de Riesgo , Sensibilidad y Especificidad , Índice de Severidad de la Enfermedad , Resultado del TratamientoRESUMEN
Fever and neutropenia is an oncologic emergency. Time-to-antibiotics (TTA) refers to the amount of time from initial provider evaluation for fever and neutropenia to intravenous antibiotic administration. Research supports that rapid time-to-antibiotics (RTTA) is associated with improved patient outcomes. This quality improvement project evaluated the success of implementing an RTTA pathway in pediatric oncology patients with fever and neutropenia. The setting was an advanced practice nurse-managed pediatric ambulatory infusion center where patients with fever and neutropenia were often evaluated and treated. In order to improve TTA, a multidisciplinary pathway was implemented with a goal of TTA that was less than 60 minutes from initial provider evaluation. Implementation of the RTTA pathway included discussion of shared expectations with the pharmacy and education departments and discussion of shared expectations with the bedside nurses and advanced practice nurses staffing the unit. Additionally, a preliminary lab test was utilized. Success of the implementation was evaluated through 2 measures: TTA and nurses' knowledge of fever and neutropenia and the importance of RTTA. The aims of this project were to improve TTA as well as nurses' knowledge of fever and neutropenia and the importance of RTTA, and both these aims were successfully attained.
Asunto(s)
Antibacterianos/administración & dosificación , Neutropenia Febril Inducida por Quimioterapia/tratamiento farmacológico , Neoplasias/enfermería , Proceso de Enfermería , Centros Médicos Académicos , Adolescente , Neutropenia Febril Inducida por Quimioterapia/complicaciones , Neutropenia Febril Inducida por Quimioterapia/enfermería , Niño , Preescolar , Vías Clínicas , Esquema de Medicación , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Neoplasias/complicaciones , Enfermería Pediátrica , Mejoramiento de la CalidadRESUMEN
BACKGROUND: A new 23S ribosomal RNA genes-targeted in situ hybridization (ISH) probe to detect global bacterial genomic DNA (59 species from 35 genera; referred to as the GB probe) phagocytized in leukocytes was recently developed. This method provided early and direct evidence of bacterial infection with high sensitivity and specificity in spontaneous bacterial peritonitis ascites. However, the utility of this method in febrile neutropenia (FN) is unknown. METHODS: We prospectively evaluated the utility of the ISH approach using the GB probe and previously reported probes in patients with neutropenia and fever undergoing chemotherapy at our institution between June 2011 and July 2013. Blood samples for culture analysis and ISH tests were collected simultaneously at the onset of fever; the latter were performed repeatedly. RESULTS: Fifty febrile episodes were evaluated. In 24 episodes of fever of unknown origin and 15 episodes of local infection (all negative for blood cultures), ISH tests identified causal bacteria in 21% and 13% of cases, respectively, at the onset of fever. In seven sepsis cases (all positive for blood culture), positive ISH test results at fever onset were achieved in 71%; for two patients with neutrophil counts of 0/µl and 171/µl, respectively, negative results were obtained. CONCLUSIONS: This new ISH approach could prove useful for early detection of bacteria in patients with neutropenia and blood culture-negative, with fever of unknown etiology after chemotherapy. Using this method in combination with blood culture, even in cases with extremely low neutrophil counts, might contribute to better management of FN.
Asunto(s)
Bacterias/aislamiento & purificación , Infecciones Bacterianas/diagnóstico , Cultivo de Sangre/métodos , Neutropenia Febril Inducida por Quimioterapia/complicaciones , ADN Bacteriano/aislamiento & purificación , Hibridación in Situ/métodos , ARN Ribosómico 23S/genética , Adulto , Anciano , Antineoplásicos/efectos adversos , Antineoplásicos/uso terapéutico , Bacterias/genética , Infecciones Bacterianas/etiología , Biomarcadores/sangre , Calcitonina/sangre , ADN Bacteriano/genética , Femenino , Genes de ARNr , Humanos , Interleucina-6/sangre , Interleucina-8/sangre , Recuento de Leucocitos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , ARN Bacteriano/genética , Sensibilidad y Especificidad , Sepsis/diagnóstico , Sepsis/microbiología , Adulto JovenRESUMEN
OBJECTIVES: Patients with suspected Neutropenic sepsis require rapid antibiotic administration, but despite extensive education, only 67% of patients received antibiotics within 60 minutes . METHODS: A Neutropenic Sepsis Alert Card was created, as a Patient Specific Directive - this allows nurses to administer antibiotics to specific patients without prior medical review. RESULTS: Since the intervention, 301 patients presented with suspected neutropenic sepsis. 277 patients (92%) received their first dose of intravenous antibiotics within 1 hour of arrival into hospital, compared to 95 out of 143 patients (67%) presenting between January and June of 2014 (p=0.036). CONCLUSION: The Neutropenic Sepsis Alert Card can significantly improve door to antibiotic needle time for chemotherapy patients with suspected neutropenic sepsis. This intervention is inexpensive and easily replicable in other health care organisations.